A Common Gut Bacterium’s Toxin Fuels Gall Bladder Cancer Growth in Mice

Early-stage research published in Nature Microbiology implicates a toxin from a common gut and biliary bacterium in driving gall bladder cancer (GBC), one of the most lethal malignancies of the digestive tract. The study by Chen J and colleagues used mouse models and human tumor tissue to trace two distinct molecular routes by which enterotoxigenic Bacteroides fragilis (ETBF) and its secreted protein, B. fragilis toxin (BFT), push the disease forward. The findings are preliminary, but they identify specific molecular targets that future therapies might exploit.

ETBF enrichment in gall bladder tumor tissue

Metagenomic shotgun sequencing of GBC tissues from 25 patients found B. fragilis among 14 bacterial species significantly enriched in tumor tissue compared to non-tumor samples. The enterotoxigenic subtype, ETBF, was detected in 50% of pre-malignant lesions and in 53.85% of invasive GBC tissues, suggesting the bacterium may be present from the earliest stages of disease rather than arriving after a tumor is established. ETBF burden was also significantly higher in tumor tissue than in adjacent para-tumor tissue or in samples from patients with chronic calculous cholecystitis, a common benign condition of the gall bladder.

This pattern echoes work on colorectal cancer, where the bft gene has been found in the colon mucosa of cancer patients at elevated rates, raising questions about whether ETBF contributes to malignancy across multiple sites in the biliary and gastrointestinal tract. In mouse experiments, oral gavage with ETBF led to confirmed bacterial colonization of the gall bladder mucosa, where it penetrated both the mucosal and muscular layers and reduced levels of key epithelial junction proteins including E-cadherin, Claudin-3, and Occludin, effectively compromising the barrier that normally protects gall bladder tissue.

Why gall bladder cancer makes this discovery urgent

Gall bladder cancer is among the most lethal biliary malignancies, with five-year survival rates that remain low largely because most cases are diagnosed at an advanced stage and effective systemic therapies are scarce. If a microbial factor is reliably present in more than half of invasive tumors, it could eventually become a target for prevention or early intervention. Roughly 15 to 20% of cancers broadly are thought to involve microbial pathogens, and identifying which organisms contribute to which tumor types is an active priority in oncology research. The biliary microbiota, long overlooked, is now attracting serious attention as a potential driver of biliary tract malignancies.

Two molecular pathways connecting BFT to tumor growth

The study's most mechanistically detailed contribution is the identification of two parallel routes by which ETBF promotes GBC, both dependent on BFT, its 20-kilodalton zinc-dependent metalloprotease toxin.

The first route runs through adhesion. ETBF was shown to adhere preferentially to GBC cells compared to normal gall bladder cells. Biotin pull-down and co-immunoprecipitation assays identified MltD, a 49-kilodalton bacterial outer membrane protein, as the adhesion factor responsible. MltD binds directly to TMPRSS13, a host cell surface receptor that is highly expressed in GBC cell lines but not in normal gall bladder cells. Once ETBF attaches via this MltD-TMPRSS13 interaction, it activates the JAK2-STAT3 signaling pathway inside GBC cells, driving proliferation. Critically, BFT itself upregulates TMPRSS13 by activating NF-kB p65, which binds the TMPRSS13 promoter: the toxin effectively turns up the expression of its own docking receptor on tumor cells, a self-reinforcing mechanism.

The second route is immunological. ETBF-treated GBC cells secreted substantially more CXCL1, the most significantly upregulated chemokine in RNA sequencing data from treated cells. CXCL1 recruits myeloid-derived suppressor cells (MDSCs), a class of immune cells that suppress anti-tumor immunity and promote new blood vessel formation. In mouse allograft experiments, ETBF-injected tumors showed higher MDSC proportions and enhanced angiogenesis compared to controls. Treating mice with bevacizumab, an anti-VEGF antibody, or depleting MDSCs directly both reversed BFT-mediated tumor growth and angiogenesis, confirming that this immune route is functionally important.

BFT alone, added as conditioned medium or as a recombinant protein, was insufficient to directly stimulate GBC cell proliferation in cell culture experiments, indicating that ETBF's full pro-tumorigenic effect requires the intact bacteria and its adhesion machinery, not just the free toxin.

Limitations of the current evidence

Several important caveats constrain how far these findings can be taken. The in vivo experiments relied on subcutaneous allograft models in nude mice, which lack a fully functional immune system and do not replicate the orthotopic environment of the gall bladder. As the researchers note, no spontaneous or orthotopic GBC mouse model fully recapitulates the human immune microenvironment, which limits conclusions about how ETBF reshapes anti-tumor immunity in people. Establishing definitive causality in humans remains a significant challenge. The study also does not resolve whether TMPRSS13 or other host proteins serve as direct receptors for BFT itself, or whether additional regulatory mechanisms operate upstream of the pathways described.

More broadly, the molecular mechanisms of BFT-mediated pathogenesis remain incompletely mapped even in colorectal cancer, where the bacterium has been studied far longer. GBC is a comparatively understudied malignancy, and replication in larger patient cohorts will be essential before any clinical application is possible.

Therapeutic targets the study opens up

Despite these limitations, the study sketches a plausible target landscape. The MltD-TMPRSS13 adhesion axis is a candidate for disruption: blocking the bacterium's ability to dock to tumor cells could in principle interrupt both downstream signaling routes simultaneously. CXCL1 and MDSC recruitment represent a second intervention point, and bevacizumab already has regulatory approval for other cancers, giving researchers an existing tool to test in GBC contexts. Bacterial toxins and their engineered derivatives are also attracting interest as antitumor agents in their own right, and a deeper understanding of how BFT interacts with host receptors could inform that line of work as well. For now, the findings from Chen J and colleagues add gall bladder cancer to the growing list of malignancies where the microbial inhabitants of the tumor deserve a hard look as potential therapeutic vulnerabilities.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• Causal mechanisms were established primarily in mouse allograft models and cell lines; definitive causality in humans has not been demonstrated.
• The human tissue dataset is small (25 patients for metagenomic sequencing), limiting generalizability.
• No orthotopic or spontaneous GBC mouse model was used, so the full human immune context is not captured.
• Funding source was not disclosed by the authors.

Mechanistic study combining metagenomic analysis of 25 patient tissue samples with in vitro cell line and organoid experiments and mouse allograft models. Demonstrates association between ETBF enrichment and gall bladder cancer in human tissues, and establishes causal pathways in preclinical systems; causality in humans remains unconfirmed. Findings have not yet been independently replicated.

References

1. Jun Chen, Yang An, Aiyanlun Tong, et al. (2026). Bacteroides fragilis toxin promotes gall bladder cancer in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02404-5
2. Annemarie Boleij, Elizabeth M. Hechenbleikner, Andrew C. Goodwin, et al. (2014). The Bacteroides fragilis Toxin Gene Is Prevalent in the Colon Mucosa of Colorectal Cancer Patients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciu787
3. Epidemiology of gallbladder cancer – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944208/
4. Luz Ibarra-Velázquez, Marco Cardona-López, Reynaldo Cervantes-Figueroa, Alba Ascencio-Navarrate, María Becerra-Mercado, Ana Madriz-Elisondo (2026). The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future. Microorganisms. https://doi.org/10.3390/microorganisms14050964